ABSTRACT Background and Aim Existing literature largely contrasts pediatric inflammatory bowel disease (PIBD) phenotypic differences and outcomes of South Asians (SAs) with Caucasians. No published comparative data exist between SAs and non‐SAs within Asia‐Pacific.
James Guoxian Huang+4 more
wiley +1 more source
Risk of new-onset and recurrent uveitis with different biologics for ankylosing spondylitis: a network meta-analysis. [PDF]
Zhao X+5 more
europepmc +1 more source
The Dental Status of Patients Taking Common Biologic Agents: A Single‐Center Cross‐Sectional Study
ABSTRACT Objectives Despite expanding use and medical applications, little is known about the impact of biologic agents (BAs) on dental treatment. The aim of this study was to investigate the dental status of patients on common classes of BAs to understand treatment needs and use in this population.
Shivani Shah+4 more
wiley +1 more source
Association of the TNFRSF1B-rs1061622 variant with nonresponse to infliximab in ulcerative colitis. [PDF]
Tessier L+9 more
europepmc +1 more source
Racial Differences in Disease Characteristics of Pediatric Hidradenitis Suppurativa
ABSTRACT Understanding the potential racial differences in presentation, severity, and outcomes of pediatric hidradenitis suppurativa (HS) can help deliver equitable and individualized care, especially as this condition is increasingly being acknowledged in this population.
Toluwalashe Onamusi+2 more
wiley +1 more source
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea. [PDF]
Kwon OC+6 more
europepmc +1 more source
Blau Syndrome (Juvenile Systemic Granulomatosis): State‐Of‐The‐Art Review
ABSTRACT Blau syndrome (BlauS) is a rare pediatric autoinflammatory disorder due to NOD2 gain‐of‐function pathogenic variants characterized by a triad of granulomatous dermatitis, arthritis, and uveitis, which can progress to systemic complications if untreated.
Ou Jia (Emilie) Wang+3 more
wiley +1 more source
The Effects of the Biological Agents Infliximab, Vedolizumab, and Ustekinumab on Intestinal Anastomosis: An Experimental Study in Rats. [PDF]
Menni A+10 more
europepmc +1 more source